Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Apararenone in Healthy Men
NCT02900235Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apararenone in diabetic nephropathy (DN) and Nonalcoholic steatohepatitis (NASH), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Total radioactivity in urine and faeces up to 99 days, Maximum observed plasma concentration up to 99 days and 5 more. Started Aug 2016; status: completed.
02
Drugs
apararenone
03
Conditions
diabetic nephropathy (DN)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02900235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900235.